Sample
|
Yeara
|
Lineage
|
Spoligo. family
|
Drug susceptibility test phenotype
|
---|
INH
|
RIF
|
STR
|
ETB
|
PZA
|
RFB
|
ETH
|
AMK
|
CAP
|
OFX
|
MOX
|
PAS
|
LZ
|
KANb
|
Resistance phenotype
|
---|
POR1
|
2007
|
4.3.4.2
|
LAM4
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
S
|
R
|
XDR-TB
|
POR2
|
2007
|
4.1.1.1
|
X2
|
R
|
R
|
S
|
S
|
S
|
R
|
R
|
S
|
S
|
S
|
S
|
S
|
S
|
-
|
MDR-TB
|
POR3
|
2007
|
4.3.4.2
|
LAM1
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
S
|
S
|
R
|
XDR-TB
|
POR4
|
2007
|
4.3.4.2
|
LAM1
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
S
|
R
|
R
|
S
|
S
|
R
|
XDR-TB
|
POR5
|
2007
|
4.3.4.2
|
LAM4
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
S
|
S
|
S
|
S
|
S
|
S
|
-
|
MDR-TB
|
POR6
|
2008
|
4.3.4.2
|
LAM4
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
S
|
S
|
R
|
XDR-TB
|
POR7
|
2009
|
4.3.4.2
|
LAM4
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
S
|
S
|
R
|
XDR-TB
|
POR8
|
2012
|
4.3.4.2
|
LAM4
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
S
|
S
|
R
|
XDR-TB
|
POR9
|
2011
|
4.3.4.2
|
LAM4
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
S
|
R
|
XDR-TB
|
POR10
|
2013
|
4.2.1
|
Ural H3/4
|
R
|
R
|
R
|
R
|
R
|
R
|
R
|
S
|
S
|
S
|
S
|
S
|
S
|
R
|
MDR-TB
|
H37Rv
|
-
|
4.9
|
H37RV
|
S
|
S
|
S
|
S
|
S
|
S
|
S
|
S
|
S
|
S
|
S
|
S
|
S
|
-
|
Pan-susceptible
|
-
MDR-TB multidrug-resistant TB, XDR-TB extensively drug-resistant TB, INH isoniazid, RIF rifampicin, STR streptomycin, ETB ethambutol, PZA pyrazinamide, RFB rifabutin, ETH ethionamide, AMK amikacin, CAP capreomycin, OFX ofloxacin, MOX moxifloxacin, PAS para-aminosalicylic acid, LZ linezolid, KAN kanamycin, S “susceptible”, R “resistant”
- Bold indicates discrepant calls by Mykrobe Predictor, underlining indicates discrepant calls by TBProfiler
-
aYear of collection
-
bDrug susceptibility test not performed, with status inferred by the TBProfiler library